The company's GenSci098 injection is a Class I new drug for therapeutic biological products. It is a humanized anti-TSHR antagonist monoclonal antibody that specifically binds to the thyroid stimulating hormone receptor (TSHR) to block its binding with autoantibodies to trigger the release of inflammatory factors and the production of hyaluronic acid (HA). Preclinical data show that GenSci098 has the potential to be used as a new treatment for TED. During the reporting period, GenSci098 injection has completed the submission of China IND.